- Home
- NKTR vs IAF Comparison
NKTR vs IAF Comparison
Compare NKTR & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- IAF
- Stock Information
- Founded
- NKTR 1990
- IAF 1985
- Country
- NKTR United States
- IAF United States
- Employees
- NKTR N/A
- IAF N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- IAF Finance/Investors Services
- Sector
- NKTR Health Care
- IAF Finance
- Exchange
- NKTR Nasdaq
- IAF Nasdaq
- Market Cap
- NKTR 125.5M
- IAF 103.9M
- IPO Year
- NKTR 1994
- IAF N/A
- Fundamental
- Price
- NKTR $8.51
- IAF $4.42
- Analyst Decision
- NKTR Strong Buy
- IAF
- Analyst Count
- NKTR 6
- IAF 0
- Target Price
- NKTR $73.75
- IAF N/A
- AVG Volume (30 Days)
- NKTR 348.5K
- IAF 90.4K
- Earning Date
- NKTR 08-07-2025
- IAF 01-01-0001
- Dividend Yield
- NKTR N/A
- IAF 11.44%
- EPS Growth
- NKTR N/A
- IAF N/A
- EPS
- NKTR N/A
- IAF N/A
- Revenue
- NKTR $87,248,000.00
- IAF N/A
- Revenue This Year
- NKTR N/A
- IAF N/A
- Revenue Next Year
- NKTR N/A
- IAF N/A
- P/E Ratio
- NKTR N/A
- IAF N/A
- Revenue Growth
- NKTR N/A
- IAF N/A
- 52 Week Low
- NKTR $6.48
- IAF $3.60
- 52 Week High
- NKTR $22.79
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- NKTR 42.19
- IAF 59.58
- Support Level
- NKTR $7.99
- IAF $4.40
- Resistance Level
- NKTR $9.71
- IAF $4.51
- Average True Range (ATR)
- NKTR 1.37
- IAF 0.06
- MACD
- NKTR -0.20
- IAF -0.01
- Stochastic Oscillator
- NKTR 11.66
- IAF 65.91
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.